Several drugs are set for first round of Medicare price negotiations

The Centers for Medicare & Medicaid Services has named a list of 10 drugs that will be up for the first price negotiations under the Inflation Reduction Act (IRA).

The drugs that made the price negotiation cut account for more than $45 billion in Medicare Part D spending from June 2022 to May 2023. They are Johnson & Johnson’s Imbruvica, Stelara and Xarelto plus Bristol Myers Squibb’s Eliquis, Merck & Co.’s Januvia, Novartis’ Entresto, Eli Lilly’s Jardiance, AstraZeneca’s Farxiga, Novo Nordisk’s Fiasp and Amgen’s Enbrel.

A meeting is scheduled for this fall.

Click here to read the entire article.